Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions

Anti-inflammatory activity of the bradykinin B1R antagonist in a model of LPS-induced lung inflammation in cynomolgus monkey

Thierry Bouyssou, Birgit Jung, Peter Nickolaus, Jeff Duan, Feihong Dai, Henri Doods
European Respiratory Journal 2016 48: PA5063; DOI: 10.1183/13993003.congress-2016.PA5063
Thierry Bouyssou
1Inflammation & Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Baden-WürttembergGermany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Birgit Jung
1Inflammation & Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Baden-WürttembergGermany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Nickolaus
1Inflammation & Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Baden-WürttembergGermany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeff Duan
2PharmaLegacy Laboratories, PharmaLegacy Laboratories, Inc., Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Feihong Dai
2PharmaLegacy Laboratories, PharmaLegacy Laboratories, Inc., Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henri Doods
1Inflammation & Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Baden-WürttembergGermany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

A model of LPS-induced lung inflammation in cynomolgus monkeys was developed to compare the anti-inflammatory activity of bradykinin B1R antagonist to those of a PDE4 inhibitor and dexamethasone.

6 naive cynomolgus monkeys (6 kg) were challenged once a week. In the first week, bronchoalveolar lavage (BAL) was collected from the left lung (flushed with 10 mL PBS solution), using a pediatric bronchoscope under anaesthesia (zoletil, xylazine). In the second week, BAL was performed 12 h after intratracheal LPS nebulization for 5 min (20 µg/kg). In addition, the monkeys received the vehicle (0.5% CMC) orally 1 h before and 6 h after LPS. In weeks 3, 4 and 5, the animals were challenged with LPS and they received at random the test compound orally bid: B1R antagonist (30 mg/kg), PDE4 inhibitor (0.5 mg/kg) or dexamethasone (1 mg/kg). BAL was performed 12 h after LPS challenge. BALF total cell count, differential cell count, BALF protein, and BALF IL-8 were measured.

At 12 h post LPS, BAL cells were elevated (p < 0.05) over baseline (LPS: 20.106 vs naive: 2.106, neutrophils LPS: 77 % vs naive: 1.8 %), BALF protein was increased (p < 0.05) (LPS: 3 mg/ml vs naive: 0.8 mg/ml) and BALF IL-8 was increased (p < 0.05) (LPS: 1.1 ng/ml vs naive: 0.2 ng/ml). All inflammatory parameters returned to baseline level one week after LPS challenge. All treatments, B1R antagonist, PDE4 inhibitor and dexamethasone, reduced (p < 0.05) LPS-induced BAL neutrophilia (80 % inhibition), BALF protein (90 % inhibition) and BALF IL-8 (80 % inhibition).

These data show that the anti-inflammatory activity of the B1R antagonist was similar to the activity of dexamethasone and the PDE4 inhibitor.

  • Pharmacology
  • Lung injury
  • Inflammation
  • Copyright ©the authors 2016
Previous
Back to top
Vol 48 Issue suppl 60 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Anti-inflammatory activity of the bradykinin B1R antagonist in a model of LPS-induced lung inflammation in cynomolgus monkey
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Anti-inflammatory activity of the bradykinin B1R antagonist in a model of LPS-induced lung inflammation in cynomolgus monkey
Thierry Bouyssou, Birgit Jung, Peter Nickolaus, Jeff Duan, Feihong Dai, Henri Doods
European Respiratory Journal Sep 2016, 48 (suppl 60) PA5063; DOI: 10.1183/13993003.congress-2016.PA5063

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Anti-inflammatory activity of the bradykinin B1R antagonist in a model of LPS-induced lung inflammation in cynomolgus monkey
Thierry Bouyssou, Birgit Jung, Peter Nickolaus, Jeff Duan, Feihong Dai, Henri Doods
European Respiratory Journal Sep 2016, 48 (suppl 60) PA5063; DOI: 10.1183/13993003.congress-2016.PA5063
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Combining an epithelial repair factor and anti-fibrotic with a corticosteroid offers optimal treatment for the pathogenesis of allergic airways disease
  • Pharmacological characterization of the mechanism of action leading to synergism between glycopyrronium bromide and indacaterol fumarate
  • Neutrophils in bronchial mucosa, sputum and blood after administration of the CXCR2-antagonist AZD5069 - An explorative study in neutrophilic asthma
Show more 5.1 Airway Pharmacology and Treatment

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society